Novo Nordisk has initiated a share repurchase programme worth up to DKK 15 billion, starting from February 4, 2026, and running for 12 months. As of May 22, 2026, the company has repurchased over 17 million B shares at an average price of DKK 262.22 per share, totaling about DKK 4.47 billion. This buyback aims to return value to shareholders and optimize the company's capital structure. Novo Nordisk currently holds 0.8% of its shares as treasury stock and plans to continue repurchasing shares under this programme through early 2027.
Novo Resources Corp has regained full control of the Egina Gold Project in Western Australia's Pilbara region after Northern Star Resources withdrew from their earn-in agreement. Northern Star decided not to proceed with the additional A$18 million e...
Novo Nordisk's POSEIDON study of 18,904 patients across 18 countries found that 40% of people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure have cardiovascular inflammation. This inflammation, mea...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
